ストックスクリーナーアプリを入手
0.474
8.16%
-0.0421
プレマーケット:
.48
0.006
+1.27%
前日終値:
$0.5161
開ける：
$0.5199
24時間の取引高:
1.96M
Relative Volume:
0.57
時価総額：
$23.46M
収益：
-
当期純損益:
$-29.77M
株価収益率:
-0.031
EPS:
-15.2954
ネットキャッシュフロー:
$-24.23M
1週間 パフォーマンス:
+2.66%
1か月 パフォーマンス:
+24.31%
6か月 パフォーマンス:
-35.17%
1年 パフォーマンス:
-80.49%
1日の値動き範囲:
$0.4652
$0.52
1週間の範囲:
$0.4617
$0.525
52週間の値動き範囲:
$0.25
$3.6499
Moleculin Biotech Inc Stock (MBRX) Company Profile
MBRX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MBRX
Moleculin Biotech Inc
|
0.474 | 25.55M | 0 | -29.77M | -24.23M | -15.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Moleculin Biotech Inc Stock (MBRX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-06-09 | 再開されました | H.C. Wainwright | Buy |
| 2025-02-12 | ダウングレード | Maxim Group | Buy → Hold |
| 2022-07-18 | 再開されました | Oppenheimer | Outperform |
Moleculin Biotech Inc (MBRX) 最新ニュース
Can machine learning forecast Moleculin Biotech Inc. recoveryJuly 2025 Trends & Community Consensus Picks - newser.com
Visual analytics tools that track Moleculin Biotech Inc. performanceMarket Sentiment Review & Growth Focused Stock Pick Reports - newser.com
Will Moleculin Biotech Inc. stock go up soon2025 Dividend Review & Community Driven Trade Alerts - newser.com
Is Moleculin Biotech Inc. stock overvalued by current metrics2025 Fundamental Recap & Short-Term High Return Strategies - newser.com
Technical signs of recovery in Moleculin Biotech Inc.Weekly Gains Report & Stepwise Entry/Exit Trade Alerts - newser.com
Moleculin Biotech Inc. stock momentum explainedJuly 2025 WrapUp & Accurate Trade Setup Notifications - newser.com
Analyzing Moleculin Biotech Inc. with multi timeframe chartsWeekly Profit Summary & Long-Term Capital Growth Strategies - newser.com
How to escape a deep drawdown in Moleculin Biotech Inc.2025 Big Picture & Free Daily Entry Point Trade Alerts - newser.com
Can Moleculin Biotech Inc. (MOL) stock stage a strong rebound this quarter - newser.com
How to build a dashboard for Moleculin Biotech Inc. stockInflation Watch & Safe Entry Point Identification - newser.com
Will earnings trigger a reversal in Moleculin Biotech Inc.Trade Performance Summary & Low Drawdown Investment Ideas - newser.com
Can Moleculin Biotech Inc. (MOL) stock hold up in economic slowdown2025 Trading Volume Trends & Free Weekly Chart Analysis and Trade Guides - newser.com
Moleculin Biotech Secures $6 Million Through Warrant Agreement - MSN
Moleculin Biotech (NASDAQ:MBRX) Stock Rating Lowered by Wall Street Zen - Defense World
MBRXMoleculin Reports Second Quarter 2025 Financial Results and Highlights - ADVFN
Moleculin receives notice of intent to grant new European patent for Annamycin - MSN
What drives Moleculin Biotech Inc MOL stock priceFibonacci Extensions & High Profit Trading Plans - earlytimes.in
What analysts say about Moleculin Biotech Inc stockVolume Analysis Techniques & Low Risk Capital Growth Plans - earlytimes.in
What Technical Indicators Signal for GOCL Corporation Limited Next MonthAutomated Trading Signals & Discover Top Gainers in Every Sector - earlytimes.in
Moleculin Biotech Inc Stock Analysis and ForecastSupport Level Holds & Grow Generational Wealth With Ease - Early Times
What analysts say about Kekrops SA KE1 stockAnalyst Downgrades & Superior Growth Trading - Early Times
Moleculin Biotech announces issuance of Canadian patent covering Annamycin - Yahoo Finance
Moleculin Announces Notice of Allowance for Canadian Patent Covering Annamycin - GlobeNewswire
Moleculin receives Canadian patent allowance for cancer drug Annamycin By Investing.com - Investing.com Nigeria
Moleculin Biotech Secures Canadian Patent for Annamycin - TipRanks
Moleculin Biotech (MBRX) Awaits Canadian Patent for Annamycin In - GuruFocus
Moleculin receives Canadian patent allowance for cancer drug Annamycin - Investing.com
First Non-Cardiotoxic Anthracycline: Moleculin's Annamycin Gains Canadian Patent Protection Until 2040 - Stock Titan
Certain Restricted Stock Units of Moleculin Biotech, Inc. are subject to a Lock-Up Agreement Ending on 22-SEP-2025. - MarketScreener
Certain Options of Moleculin Biotech, Inc. are subject to a Lock-Up Agreement Ending on 22-SEP-2025. - MarketScreener
Can Moleculin Biotech Inc. grow without dilutionJuly 2025 Recap & Advanced Swing Trade Entry Alerts - خودرو بانک
Moleculin Biotech Inc (MBRX) 財務データ
収益
当期純利益
現金流量
EPS
Moleculin Biotech Inc (MBRX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| KLEMP WALTER V | CEO and President |
Jun 23 '25 |
Buy |
0.37 |
675,675 |
250,000 |
743,607 |
5.74%
大文字化:
|
ボリューム (24 時間):